PF-06423264
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Normal Healthy
Conditions
Normal Healthy
Trial Timeline
May 23, 2016 → May 23, 2017
NCT ID
NCT02778477About PF-06423264
PF-06423264 is a phase 1 stage product being developed by Pfizer for Normal Healthy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02778477. Target conditions include Normal Healthy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02778477 | Phase 1 | Terminated |
Competing Products
20 competing products in Normal Healthy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Roxadustat | Astellas Pharma | Phase 1 | 33 |
| Donepezil | Eisai | Approved | 85 |
| eribulin mesylate | Eisai | Phase 2 | 52 |
| Lurasidone HCl | Sumitomo Pharma | Phase 1 | 33 |
| Eybelis ophthalmic solution 0.002% | Santen Pharmaceutical | Approved | 85 |
| Triptorelin | Merck | Pre-clinical | 23 |
| Temozolomide + Vorinostat | Merck | Phase 2 | 52 |
| LDE225 | Novartis | Phase 1 | 33 |
| LDK378 | Novartis | Phase 1 | 33 |
| cyclosporine micro-emulsion | Novartis | Approved | 85 |
| LDK378 | Novartis | Phase 1 | 33 |
| LEE011 | Novartis | Phase 1 | 33 |
| LEE011 | Novartis | Phase 1 | 33 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| filgrastim | Amgen | Pre-clinical | 22 |
| PF-05221304 | Pfizer | Phase 1 | 32 |
| BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose Solution | Bristol Myers Squibb | Phase 1 | 32 |
| tolebrutinib | Sanofi | Phase 1 | 32 |
| Venglustat (GZ402671) | Sanofi | Phase 1 | 32 |
| Rilzabrutinib | Sanofi | Phase 1 | 32 |